Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1/2, Open-label, Single Dose Study of SKY-GJB2 Given as a Single Unilateral Intracochlear Administration in Pediatric Subjects With GJB2-mediated Hearing Loss

Skylark Bio is conducting a study of an investigational new drug called SKY-GJB2 and its delivery device, the SKY-CAT. SKY-GJB2 is a gene therapy that is being…

GJB2-mediated Hearing LossGJB2 Gene MutationDFNB1A

Estimated

~$10 – $8,750

Skylark Bio Inc.NCT07627971